Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$24.65
+1.6%
$27.68
$22.01
$33.71
$4.17B0.551.91 million shs1.74 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$73.12
-1.2%
$69.41
$45.50
$84.89
$7.08B1.02946,703 shs736,511 shs
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$199.92
+0.1%
$198.62
$23.27
$199.98
$9.56B-0.49913,102 shs1.86 million shs
Zai Lab Limited stock logo
ZLAB
Zai Lab
$15.66
+3.6%
$17.70
$13.48
$39.50
$1.55B1.1632,461 shs430,126 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+0.79%+2.06%-11.10%-13.73%-16.86%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-0.71%-7.30%+7.23%+11.98%+18.89%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00%0.00%0.00%0.00%+2.84%
Zai Lab Limited stock logo
ZLAB
Zai Lab
+0.87%+4.85%-6.55%-34.26%-57.89%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.6376 of 5 stars
4.31.00.04.21.42.52.5
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
4.3018 of 5 stars
3.52.00.04.53.72.50.6
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
1.5985 of 5 stars
3.52.00.00.01.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.50
Moderate Buy$35.3843.51% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.90
Moderate Buy$90.1723.31% Upside
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
2.00
Hold$200.000.04% Upside
Zai Lab Limited stock logo
ZLAB
Zai Lab
3.00
Buy$64.22310.11% Upside

Current Analyst Ratings

Latest ITCI, RXDX, ALKS, and ZLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$120.00
4/23/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $107.00
4/22/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $90.00
4/22/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $96.00
4/19/2024
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$35.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $90.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$83.00 ➝ $103.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $91.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$67.00 ➝ $77.00
4/16/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
4/9/2024
Alkermes plc stock logo
ALKS
Alkermes
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $50.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.66B2.51$2.33 per share10.60$7.21 per share3.42
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$462.18M15.32N/AN/A$6.15 per share11.89
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$6.81M1,403.55N/AN/A$16.12 per share12.40
Zai Lab Limited stock logo
ZLAB
Zai Lab
$266.72M5.82N/AN/A$8.05 per share1.95

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$355.76M$2.0711.9111.790.6521.39%16.10%9.15%5/1/2024 (Confirmed)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$1.46N/A81.24N/A-30.08%-23.02%-19.39%5/2/2024 (Estimated)
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
-$141.75M-$3.52N/AN/AN/A-3,768.76%-33.50%-29.59%N/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$334.62M-$3.45N/AN/AN/A-125.46%-37.07%-30.72%5/8/2024 (Confirmed)

Latest ITCI, RXDX, ALKS, and ZLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$0.83N/A+$0.83N/AN/AN/A  
5/1/2024N/A
Alkermes plc stock logo
ALKS
Alkermes
$0.6130N/A-$0.6130N/AN/AN/A  
2/27/2024Q4 2023
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$0.87-$0.98-$0.11-$0.98$70.41 million$65.83 million
2/22/2024Q4 2023
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.44-$0.30+$0.14-$0.30$135.97 million$132.10 million    
2/15/2024Q4 23
Alkermes plc stock logo
ALKS
Alkermes
$0.51$0.22-$0.29$0.02$362.78 million$377.50 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.24
2.86
2.50
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
5.41
5.31
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.04
37.56
37.56
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/A
4.63
4.41

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
92.66%
Zai Lab Limited stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.76%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
3.40%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
3.40%
Zai Lab Limited stock logo
ZLAB
Zai Lab
5.23%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,100169.18 million161.13 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
61096.81 million93.52 millionOptionable
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
9747.81 million46.19 millionNot Optionable
Zai Lab Limited stock logo
ZLAB
Zai Lab
2,17599.21 million94.02 millionOptionable

ITCI, RXDX, ALKS, and ZLAB Headlines

SourceHeadline
Zai Lab (NASDAQ:ZLAB) Shares Up 5.3%Zai Lab (NASDAQ:ZLAB) Shares Up 5.3%
marketbeat.com - April 24 at 3:36 PM
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07
marketbeat.com - April 22 at 12:00 PM
Zai Lab Ltd. ADRZai Lab Ltd. ADR
wsj.com - April 21 at 8:26 PM
Zai Lab Limited (ZLAB)Zai Lab Limited (ZLAB)
finance.yahoo.com - April 19 at 1:02 AM
Zai Lab (NASDAQ:ZLAB)  Shares Down 2.4% Zai Lab (NASDAQ:ZLAB) Shares Down 2.4%
marketbeat.com - April 17 at 11:58 AM
Genesis Investment Management LLP Sells 339,503 Shares of Zai Lab Limited (NASDAQ:ZLAB)Genesis Investment Management LLP Sells 339,503 Shares of Zai Lab Limited (NASDAQ:ZLAB)
marketbeat.com - April 17 at 11:55 AM
A Risky Bet: Zai Labs Uncertain FutureA Risky Bet: Zai Lab's Uncertain Future
seekingalpha.com - April 16 at 7:13 PM
Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low at $14.01Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low at $14.01
marketbeat.com - April 16 at 1:41 PM
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
businesswire.com - April 15 at 7:30 AM
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
businesswire.com - April 15 at 7:30 AM
Zai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesZai Lab Statement on Executive Management Team’s Agreement on Share Activities
finance.yahoo.com - April 11 at 12:31 PM
Zai Lab Statement on Executive Management Teams Agreement on Share ActivitiesZai Lab Statement on Executive Management Team's Agreement on Share Activities
businesswire.com - April 11 at 7:30 AM
Zai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $15.13Zai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $15.13
marketbeat.com - April 10 at 3:24 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
markets.businessinsider.com - April 9 at 12:42 PM
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49
marketbeat.com - April 9 at 11:25 AM
Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in StockZai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in Stock
insidertrades.com - April 6 at 7:57 AM
Frazor Titus Edmondson III Sells 885 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockFrazor Titus Edmondson III Sells 885 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock
insidertrades.com - April 4 at 7:09 AM
Zai Lab Limited (NASDAQ:ZLAB) Insider Sells $14,292.75 in StockZai Lab Limited (NASDAQ:ZLAB) Insider Sells $14,292.75 in Stock
marketbeat.com - April 4 at 12:21 AM
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month Low at $15.53Zai Lab (NASDAQ:ZLAB) Sets New 12-Month Low at $15.53
marketbeat.com - April 3 at 12:47 PM
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
businesswire.com - April 2 at 7:30 AM
Zai Lab reports Krazati lung cancer study meets primary endpointZai Lab reports Krazati lung cancer study meets primary endpoint
msn.com - April 1 at 4:01 PM
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years agoShareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
finance.yahoo.com - April 1 at 4:01 PM
One Good, One Bad News For Bristol Myers Squibbs Marketed Drugs: DetailsOne Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
msn.com - April 1 at 11:01 AM
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
finance.yahoo.com - April 1 at 11:01 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alkermes logo

Alkermes

NASDAQ:ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Intra-Cellular Therapies logo

Intra-Cellular Therapies

NASDAQ:ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Prometheus Biosciences logo

Prometheus Biosciences

NASDAQ:RXDX
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
Zai Lab logo

Zai Lab

NASDAQ:ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.